pre-IPO PHARMA

COMPANY OVERVIEW

Karus is a leader in the design and development of innovative cancer therapeutics. Their orally-active, small molecule drugs combine targeted cancer cell activity with immunotherapy for the treatment of hematological and solid tumors.


LOCATION

  • Oxfordshire, , UK

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.karustherapeutics.com/


    CAREER WEBSITE

    https://www.karustherapeutics.com/careers


    SOCIAL MEDIA


    INVESTORS

    ip-group new-leaf-capital-partners sv-health-investors


    PRESS RELEASES


    Dec 4, 2019

    Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH


    Sep 18, 2017

    Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial


    Oct 5, 2016

    Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center


    Dec 10, 2015

    Karus Therapeutics Announces Strategic Collaboration with The University of Texas MD Anderson Cancer Center


    Dec 17, 2012

    Karus Therapeutics Announces Collaboration with Babraham Institute to Explore PI3 Kinase Inhibitors in the Treatment of Inflammatory Diseases


    For More Press Releases


    Google Analytics Alternative